HOME >> MEDICINE >> NEWS
Scientists show drug can counteract muscular dystrophy in mice

Scientists at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other institutions have demonstrated for the first time that a single drug can rebuild damaged muscle in two strains of mice that develop diseases comparable to two human forms of muscular dystrophy. This advance, which is reported online in Nature Medicine, is the latest from a research collaboration that began several years ago by the teams of Vittorio Sartorelli, M.D., at NIAMS and Pier Lorenzo Puri, M.D., Ph.D., now at Dulbecco Telethon Institute (DTI) in Rome, Italy and The Burnham Institute in La Jolla, Calif.

The scientists tested trichostatin A (TSA), an inhibitor of the enzyme deacetylase, in two mouse models of muscular dystrophy (MD): one that naturally develops a disease similar to Duchenne muscular dystrophy in humans, the other genetically altered to develop a form of dystrophy similar to the human limb-girdle muscular dystrophy. At 45 to 90 days of age, the muscles of the MD mice showed much fibrous tissue and infiltration of inflammatory cells. Unlike healthy mice, the mice with MD were unable to either run on a treadmill or swim. MD mice given TSA daily for two to three months, however, were virtually indistinguishable from healthy mice, and biophysical studies showed virtually no difference between the muscle strength of the mice with MD given the deacetylase inhibitor and healthy mice.

"This is the first example of using a drug to counteract muscular dystrophy in mouse models," says Dr. Sartorelli. Yet he points out that the drug is only promoting muscle regeneration it is not curing the defect that causes muscle deterioration. Further studies are needed to determine how long the drug works and if it works in larger animals with bigger muscles, such as dogs, before such drugs can be tested in people.

The finding has its roots in several of the group's earlier advances, the first of which was reported in 2002 in th
'"/>

Contact: Ray Fleming
flemingr@mail.nih.gov
301-496-8190
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
4-Oct-2006


Page: 1 2

Related medicine news :

1. Scientists train nano-building blocks to take on new shapes, as reported in Science
2. Scientists find war vets hand dexterity determines susceptibility to PTSD
3. Scientists develop method to track immune system enzyme in live animals
4. Scientists from the CIMA investigate a molecule for diagnosing hypertensive cardiopathy
5. Scientists equip bacteria with custom chemo-navigational system
6. Scientists find missing link to understand how plants make vitamin C
7. Scientists and polar explorers brave the elements in support of CryoSat-2
8. Scientists identify cells responsible for relapse after treatment in common childhood cancer
9. Scientists progress in successful tissue engineering
10. Scientists re-grow dental enamel from cultured cells
11. Scientists create dual-modality microbeads to improve identification of disease biomarkers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Scientists show drug can counteract muscular dystrophy mice

(Date:7/28/2015)... ... ... Morristown Medical Center, part of Atlantic Health System, today announced it was ... the nation, to implant the newly approved CoreValve® Evolut® R System from Medtronic. The ... condition. , The CoreValve® Evolut® R System was approved by the U.S. Food and ...
(Date:7/28/2015)... Francisco, California (PRWEB) , ... July 28, 2015 , ... ... the results from a recent survey (1) examining consumers’ perspectives on digital ... June 17-24, 2015, covered topics such as innovations in digital health, level of trust ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Dr. Aziz Ahmad ... The talk took place from noon to 1 p.m. Tuesday, June 23, at the ... Fla. , Dr. Ahmad is board-certified in colorectal surgery and has more than ...
(Date:7/28/2015)... ... ... to Kxan on June 24th a previously FDA approved blood pressure medication ... isradipine has garnered national attention and is making drug and alcohol rehabilitation medical physicians ... The study was conducted by the University of Texas. Human trials may be set ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... Kinetic Data announced that Schneider Electric has completed its upgrade and expansion ... a global organization with more than 170,000 employees in 134 countries supplying a ...
Breaking Medicine News(10 mins):Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 2Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 4Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 5Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4
(Date:7/28/2015)... 2015  For many medical institutions and universities, commercializing ... inventors can be a constant challenge. Taking an idea ... are rare. A new company in ... Medical Device Investments (MDI) was created to commercialize ... physicians. MDI develops, manufactures and markets the products, with ...
(Date:7/28/2015)... , July 28, 2015   CSL ... for review a Marketing Authorization Application (MAA) for ... coagulation factor IX with recombinant albumin (rIX-FP) for ... people with Hemophilia B. Upon Swissmedic approval, rIX-FP ... treatment option with dosing intervals up to 14 ...
(Date:7/28/2015)... , July 28, 2015 VirtualScopics, Inc. (NASDAQ: ... imaging solutions, today announced that it will report its ... ET market close on Tuesday, August 11, 2015.  ... and Jim Groff , chief financial officer, will ... company,s financial results and provide a business update at ...
Breaking Medicine Technology:Medical Device Investments To Become Center Of Excellence For The Commercialization Of Innovative Medical Technologies 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 3Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 4VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast 2VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast 3
Cached News: